Business Combination, Contingent Consideration, Royalty Payment Period

No definition available.

Name:	prgo_BusinessCombinationContingentConsiderationRoyaltyPaymentPeriod
Namespace Prefix:	prgo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Business Combination, Number Of Products Purchased

+ References

No definition available.

+ Details

Name:	prgo_BusinessCombinationNumberOfProductsPurchased
Namespace Prefix:	prgo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Products Sold

+ References

No definition available.

+ Details

Name:	prgo_NumberOfProductsSold
Namespace Prefix:	prgo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential Contingent Milestone Payments

+ References

No definition available.

+ Details

Name:	prgo_PotentialContingentMilestonePayments
Namespace Prefix:	prgo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=prgo_DiclofenacSodiumGel3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=prgo_OtherProductsinDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	prgo_CollaborativePartnerAxis=prgo_May2015agreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=prgo_DevelopmentstagerxproductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=prgo_ANDAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements And Other Contractual Arrangements (Details) $ in Millions					1 Months Ended	12 Months Ended
	Aug. 24, 2018 USD ($)	Dec. 20, 2017 product	Mar. 01, 2016 USD ($)	May 01, 2015 USD ($) product	Dec. 31, 2017 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development						$ 218.6	$ 167.7	$ 184.0
Payments to Acquire Intangible Assets						35.6	$ 0.0	$ 65.1
Diclo 3%
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to Acquire Intangible Assets	$ 30.4
Other products in development \| May 2015 development agreement \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty Pharma contingent milestone payments						173.0
Development-Stage Rx Products
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development				$ 18.0
Royalty Pharma contingent milestone payments			$ 30.0			17.5
Business combination, number of products purchased \| product				2
Number of products sold \| product		1
Development-Stage Rx Products \| Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty payment period			7 years
Development-Stage Rx Products \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty payment period			10 years
ANDA
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development					$ 2.5
ANDA \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty Pharma contingent milestone payments						$ 14.5